VEGF directly suppresses activation of T cells from ascites secondary to ovarian cancer via VEGF receptor type 2

Br J Cancer. 2012 Nov 20;107(11):1869-75. doi: 10.1038/bjc.2012.468.

Abstract

Background: Vascular endothelial growth factor action in tumour angiogenesis is well characterised; nevertheless, it functions as a key element in the promotion of the immune system's evasion by tumours. We sought to investigate the possible direct effect of VEGF on T-cell activation and through which type of VEGF receptor it exerts this effect on cells isolated from ovarian cancer patients' ascites.

Methods: T cells isolated from the ascites of ovarian cancer patients were cultured with anti-CD3 and IL-2, with or without VEGF for 14 days and the number of viable T cells was counted. Cytotoxic activity of cultured T cells and expression of VEGF receptor-2 (VEGFR-2), was assayed.

Results: The addition of VEGF in cultures significantly reduced the number and proliferation rate of T cells in a dose-dependent manner and CD3(+) T cells expressed VEGFR-2 on their surface upon activation. Experiments with specific anti-VEGFR-2 antibodies revealed that the direct suppressive effect of VEGF on T-cell proliferation is mediated by VEGFR-2. We also showed that VEGF significantly reduced the cytotoxic activity of T cells.

Conclusion: Our study showed that ascites-derived T cells secrete VEGF and express VEGFR-2 upon activation. Vascular endothelial growth factor directly suppresses T-cell activation via VEGFR-2.

MeSH terms

  • Ascites / immunology*
  • Female
  • Humans
  • Lymphocyte Activation / drug effects*
  • Ovarian Neoplasms / immunology*
  • T-Lymphocytes / drug effects*
  • T-Lymphocytes / immunology
  • Tumor Cells, Cultured
  • Vascular Endothelial Growth Factor A / pharmacology*
  • Vascular Endothelial Growth Factor Receptor-2 / analysis
  • Vascular Endothelial Growth Factor Receptor-2 / physiology*

Substances

  • Vascular Endothelial Growth Factor A
  • Vascular Endothelial Growth Factor Receptor-2